364 results match your criteria: "Centre d'Etude Des Pathologies Respiratoires[Affiliation]"
Mucosal Immunol
June 2023
INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032 Tours, France; Université de Tours, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032 Tours, France. Electronic address:
Bacterial respiratory infections, either acute or chronic, are major threats to human health. Direct mucosal administration, through the airways, of therapeutic antibodies (Abs) offers a tremendous opportunity to benefit patients with respiratory infections. The mode of action of anti-infective Abs relies on pathogen neutralization and crystallizable fragment (Fc)-mediated recruitment of immune effectors to facilitate their elimination.
View Article and Find Full Text PDFAnn Intensive Care
March 2023
Réanimation Polyvalente, INSERM CIC 1435 and UMR 1092, CHU Limoges, Limoges, France.
Ann Intensive Care
March 2023
Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris (APHP), Pitié-Salpêtrière Hospital, 75651, Paris Cedex 13, France.
Background: Severe hypothyroidism (SH) is a rare but life-threatening endocrine emergency. Only a few data are available on its management and outcomes of the most severe forms requiring ICU admission. We aimed to describe the clinical manifestations, management, and in-ICU and 6-month survival rates of these patients.
View Article and Find Full Text PDFJ Intensive Med
October 2022
Médecine Intensive Réanimation, CIC 1415 INSERM, CRICS-TriggerSep F-CRIN research network, CHRU de Tours, Tours France and Centre d'étude des pathologies respiratoires (CEPR), INSERM U1100, Université de Tours, Tours 37000, France.
Whereas prone positioning of intubated patients suffering from acute respiratory distress syndrome represents the standard of care, proning non-intubated patients, so-called "awake prone positioning (APP)," has only recently gained popularity and undergone scientific evaluation. In this review, we summarize current evidence on physiological and clinical effects of APP on patients' centered outcomes, such as intubation and mortality, the safety of the technique, factors and predictors of success, practical issues for optimal implementation, and future areas of research. Current evidence supports using APP among patients suffering from acute hypoxemic respiratory failure due to COVID-19 and undergoing advanced respiratory support, such as high-flow nasal cannula, in an intensive care unit setting.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 37000 Tours, France.
is a major hospital-associated pathogen that can cause severe infections, most notably in patients with cystic fibrosis (CF) or those hospitalized in intensive care units. Given its remarkable ability to resist antibiotics, eradication has grown more challenging. Therefore, there is an urgent need to discover and develop new strategies that can counteract -resistant strains.
View Article and Find Full Text PDFCrit Care
February 2023
CHRU Tours, Médecine Intensive Réanimation, Tours, France.
Lancet Respir Med
April 2023
Médecine Intensive Réanimation, CHRU Tours, CIC INSERM 1415, CRICS-TriggerSep F-CRIN Research Network, Tours, France; INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, Tours, France; Université de Tours, Tours, France. Electronic address:
Background: Fasting is frequently imposed before extubation in patients in intensive care units, with the aim to reduce risk of aspiration. This unevaluated practice might delay extubation, increase workload, and reduce caloric intake. We aimed to compare continued enteral nutrition until extubation with fasting before extubation in patients in the intensive care unit.
View Article and Find Full Text PDFPharm Res
March 2023
Université de Tours, Centre d'Étude Des Pathologies Respiratoires, INSERM U1100, Tours, France.
Front Immunol
January 2023
Interactions Hôtes-Agents Pathogènes (IHAP), Université de Toulouse, ENVT, Institut National de la Recherche Agronomique et Environnement (INRAE), Toulouse, France.
Introduction: Confronted with the emerging threat of antimicrobial resistance, the development of alternative strategies to limit the use of antibiotics or potentiate their effect through synergy with the immune system is urgently needed. Many natural or synthetic biological response modifiers have been investigated in this context. Among them, β-glucans, a type of soluble or insoluble polysaccharide composed of a linear or branched string of glucose molecules produced by various cereals, bacteria, algae, and inferior (yeast) and superior fungi (mushrooms) have garnered interest in the scientific community, with not less than 10,000 publications over the last two decades.
View Article and Find Full Text PDFCurr Opin Crit Care
February 2023
CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSep F-CRIN Research Network; and INSERM, Centre d'étude des pathologies respiratoires, U1100, Université de Tours, Tours, France.
Purpose Of Review: Since the early pandemic, prone positioning has been broadly utilized for nonintubated patients (so-called 'awake prone positioning, APP') with coronavirus disease 2019 (COVID-19) induced acute hypoxemic respiratory failure (AHRF).
Recent Findings: Numerous clinical studies have been conducted to investigate the effects of APP on oxygenation, intubation, and mortality. However, several questions remain unclear, such as the patient populations who benefit most from APP, the best length of daily duration on APP, how to improve adherence to APP, and the mechanisms of APP efficacy.
Rev Mal Respir
January 2023
CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, 2, Boulevard Tonnelé, 37000 Tours, France.
Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. Our retrospective observational study was designed to determine the efficacy and safety of sotorasib under real-life conditions in patients treated at the Tours CHRU. Our study of 15 patients showed sotorasib to be effective in 47% of cases, with overall survival of 4 months and median progression-free survival of 5.
View Article and Find Full Text PDFImmunity
December 2022
Centre d'Etude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Faculté de Médecine de Tours, 37000, Tours, France.
CD1 molecules and the MHC-related protein 1 (MR1) present lipid and small molecule antigens, respectively, for T cell surveillance. The biology of these molecules, the antigens they present, and the T cells that respond to them were recently discussed during the 12 International CD1-MR1 Meeting held in Gothenburg, Sweden.
View Article and Find Full Text PDFERJ Open Res
October 2022
Medical school, University of Tours, Tours, France.
Background: It is unclear whether delays in care affect prognosis of patients with lung cancer. The primary objective of this study was to describe the care pathway of patients diagnosed with lung cancer in a French region. Secondary objectives were to identify markers associated with 1) time from imaging to treatment and 2) with 1-year survival.
View Article and Find Full Text PDFFront Oncol
November 2022
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, United States.
Eur J Pharm Biopharm
December 2022
INSERM, Centre D'Etude Des Pathologies Respiratoires, Université François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032 Tours, France; University of Tours, Tours, France. Electronic address:
In the past decade, oral inhalation has been a thriving focus of research to administer antibody directly to the lungs as an aerosol, for local treatment of respiratory diseases. Formulation of inhaled antibodies is central for the stability of antibody, lung safety and to ensure inhaler performances. Surfactants have already been shown to prevent antibody degradation during aerosolization, but little is known about the impact of other components of liquid formulations on the structural stability of antibodies.
View Article and Find Full Text PDFMed Intensiva (Engl Ed)
November 2022
CHU de Tours, service de médecine intensive réanimation, université de Tours, Tours, France; INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), Université de Tours, France. Electronic address:
N Engl J Med
November 2022
From Centre Hospitalier Universitaire (CHU) de Poitiers, Médecine Intensive Réanimation (A.W.T., R.C., J.-P.F.), and Institut National de la Santé et de la Recherche Médicale (INSERM) Centre d'Investigation Clinique (CIC) 1402, Investigations of Sleep, Acute Lung Injury, and Ventilation (IS-ALIVE), Université de Poitiers (A.W.T., R.C., J.K., S.R., J.-P.F.), Poitiers, CHU de Rennes, Hôpital Pontchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes (A.G.), Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, INSERM CIC 1415, Critical Research in Intensive Care and Sepsis-TriggerSep Research Network, and Centre d'Etude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours (S.E.), CHU Dijon Bourgogne, Médecine Intensive Réanimation, INSERM CIC 1432, Université de Bourgogne Franche-Comté, Dijon (J.-P.Q.), Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans (M.-A.N.), Centre Hospitalier du Mans, Réanimation Médico-Chirurgicale, Le Mans (C.G.), Centre Hospitalier Victor Dupouy, Réanimation Polyvalente et Unité de Surveillance Continue, Argenteuil (D.C.), Groupe Hospitalier Régional Mulhouse Sud Alsace, site Emile Muller, Service de Réanimation Médicale, Mulhouse (G. Labro), CHU de Nantes, Médecine Intensive Réanimation, Nantes (J.R.), Centre Hospitalier Henri Mondor d'Aurillac, Service de Réanimation, Aurillac (G. Pradel), CHU de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, Université de Rouen UR3830, Rouen (G.B.), CHU Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion (L.D.), CHU de Nice, Réanimation Médicale Archet 1, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice (C.S.), CHU de Brest, Médecine Intensive Réanimation, Brest (G. Prat), Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay (G. Lacave), Centre Hospitalier Fleyriat de Bourg-en-Bresse, Réanimation Polyvalente, Bourg-en-Bresse (N.S.), CHU Grenoble Alpes, Médecine Intensive Réanimation, INSERM U1042, HP2, Université Grenoble Alpes, Grenoble (N.T.), Centre Hospitalier Bretagne Sud, Réanimation Polyvalente, Lorient (B.L.C.), Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Paris Centre, Hôpital Cochin, Médecine Intensive Réanimation, Université Paris Cité, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8104, INSERM U1016 (J.-P.M.), and AP-HP, Groupe Hospitalier Universitaire AP-HP-Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Département R3S (M.D.), Paris, Centre Hospitalier de Pau, Service de Réanimation, Pau (A. Romen), Centre Hospitalier Départemental de Vendée, Médecine Intensive Réanimation, La Roche Sur Yon (M.-A.A.), CHU de Lille, Médecine Intensive Réanimation, CNRS UMR 8576, INSERM U1285, Université de Lille, Lille (A. Rouzé), Hôpital Foch, Service de Réanimation Polyvalente, Suresnes (J.D.), Centre Hospitalier Bretagne Atlantique, Réanimation Polyvalente, Vannes (A.D.), Assistance Publique-Hôpitaux de Marseille, CHU La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille (J.B.), and Centre Jean Perrin, Unicancer, Service de Réanimation, Clermont-Ferrand (A.L.) - all in France.
Background: Spontaneous-breathing trials can be performed with the use of either pressure-support ventilation (PSV) or a T-piece. Whether PSV trials may result in a shorter time to tracheal extubation than T-piece trials, without resulting in a higher risk of reintubation, among patients who have a high risk of extubation failure is unknown.
Methods: In this multicenter, open-label trial, we randomly assigned patients who had a high risk of extubation failure (i.
Crit Care
October 2022
INSERM, IAME, Université Paris-Cité, 75006, Paris, France.
Background: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients.
Methods: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients.
Ann Intensive Care
October 2022
Médecine Intensive Réanimation, University Hospital Centre, Nantes, France.
Background: Outcomes of postresuscitation shock after cardiac arrest can be affected by targeted temperature management (TTM). A post hoc analysis of the "TTM1 trial" suggested higher mortality with hypothermia at 33 °C. We performed a post hoc analysis of HYPERION trial data to assess potential associations linking postresuscitation shock after non-shockable cardiac arrest to hypothermia at 33 °C on favourable functional outcome.
View Article and Find Full Text PDFJAMA
September 2022
CHU de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
Crit Care
September 2022
CHRU de Tours, Médecine Intensive Réanimation, 2 boulevard Tonnellé, Tours, France.
Purpose: Communication of caregivers and relatives to patients is a major difficulty in intensive care units (ICU). Patient's comprehension capabilities are variable over time and traditional comprehension tests cannot be implemented. Our purpose was to evaluate an oral comprehension test adapted for its automatic implementation using eye-tracking technology among ICU patients.
View Article and Find Full Text PDFIntensive Care Med
December 2022
Department of Anaesthesia and Intensive Care Medicine, Galway University Hospital, Saolta Hospital Group, Galway, Ireland.
J Cyst Fibros
November 2022
Parasitologie-Mycologie-Médecine Tropicale, Pôle Biologie Médicale, Hôpital Bretonneau, CHRU de, Tours 37044, France; Centre d'Etude des Pathologies Respiratoires, Inserm UMR1100, Faculté de Médecine, Université de Tours, 37032, France.
Antibodies (Basel)
August 2022
INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032 Tours, France.
Background: For the past two decades, there has been a huge expansion in the development of therapeutic antibodies, with 6 to 10 novel entities approved each year. Around 70% of these Abs are delivered through IV injection, a mode of administration allowing rapid and systemic delivery of the drug. However, according to the evidence presented in the literature, beyond the reduction of invasiveness, a better efficacy can be achieved with local delivery.
View Article and Find Full Text PDFCell Mol Immunol
December 2022
Centre d'Infection et d'Immunité de Lille, INSERM U1019, CNRS UMR 9017, Université de Lille, CHU Lille, UMS 2014 - PLBS, U1019, Institut Pasteur de Lille, 59000, Lille, France.